Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd.

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

Cara Therapeutics (CARA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.08 per share a year ago.

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Matthew Murphy - Manager, IR Christopher Posner - President, CEO & Director Ryan Maynard - CFO Scott Terrillion - Chief Compliance Officer, General Counsel & Corporate Secretary Conference Call Participants Dennis Ding - Jefferies Annabel Samimy - Stifel, Nicolaus & Company Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler & Co. Chi Fong - Bank of America Merrill Lynch Operator Thank you for standing by, and welcome to Cara Therapeutics' Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Cara Therapeutics, Inc. (CARA) Q2 2023 Earnings Call Transcript

– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

Cara Therapeutics Reports Second Quarter 2023 Financial Results

STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards.

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:00 a.m. EDT in Boston, MA.

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update.

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

Cara Therapeutics' Korsuva injection, approved for treating pruritus in adults with chronic kidney disease, may have its reimbursement period extended to 2027 by the US Medicare and Medicaid Services, potentially boosting the company's stock value. Despite a net loss of $26.7 million in Q1 2023, Cara Therapeutics has launched Kapruvia in several European countries and is progressing with Phase 3 trials for other potential treatments, indicating an active R&D pipeline. The company's financial outlook remains risky with ongoing losses and uncertainties in drug development, leading to a 70% stock devaluation since February. Cara remains a "Sell".

Cara Therapeutics Faces Uncertainty Despite Potential Reimbursement Extension For Korsuva

Paramount Group

Vimeo

Small-cap stocks, defined by a market capitalization between $300 million and $2 billion, can tempt investors looking for quick returns. However, these small-cap stocks to avoid can be incredibly volatile as they are lucrative, making them a potential danger zone for the unwary investor.

3 Small-Cap Stocks to Sell in June Before They Crash and Burn

STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 p.m. EDT in New York, NY.

Cara Therapeutics to Present at the Jefferies Healthcare Conference

NuScale Power Corp

SurgePays

Zynex Inc

CareCloud Inc

Idaho Strategic Resources Inc

TOMI Environmental Solutions

While market advocates will wince at accusations that investing is nothing more than legalized gambling, for these stocks with massive upside potential, I for one will have to concede that only speculators should read ahead. Though these enterprises may have yield lifechanging returns, they can quickly leave you in the poor house.

7 Stocks With 1,000% Upside Potential

Hibbett Sports

Inogen

1-800-FLOWERS.COM

NerdWallet

Semler Scientific

While the traditional approach to market success calls for patiently investing in reliable blue chips, those that want to see more immediate gains may consider small-cap stocks to buy. Here, the point is about accepting massive risk to hopefully realize massive rewards.

Hero or Zero? 7 Speculative Small-Cap Stocks to Make You Rich

CSL Ltd

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn.

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Christopher Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler Chi Fong - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon. My name is Lateef, and I will be your conference facilitator.

Cara Therapeutics, Inc. (CARA) Q1 2023 Earnings Call Transcript

Cara Therapeutics (CARA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.52 per share a year ago.

Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

Cara Therapeutics Reports First Quarter 2023 Financial Results

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023, at 1:30 p.m. EDT.

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

AdaptHealth Corp

Infinity Pharma

OptimizeRx Corp

Alpha Teknova

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company's efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

Cara Therapeutics recently reported their Q4 earnings that revealed an EPS loss of $0.56 per share, which was 75% lower than estimates. Revenues were $3.3M, missing estimates by $11.24M. The big miss on earnings triggered a strong sell-off with the share price basically being cut in half.

Cara Therapeutics: Looking To Place A Bid After A Big Miss On Earnings

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler AJ Velasquez-Mao - Jefferies Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Oren Livnat - H.C.

Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript

Calavo Growers

Markets finished mixed on Monday. Calavo suffered from the downward price impact of supply gluts of avocados from Mexico.

These 2 Stocks Are Plunging After Hours Monday

Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Cara Therapeutics Stock (CARA)